The Bayer Corporation has settled 651 cases related to blood clots from the use of Yasmin and Yaz. Although the drugs are often marketed as a cure-all for PMDD and premenstrual syndrome, they have also been known to cause sometimes-fatal clots. The company is responsible for paying $142 million in compensation. However, it only settles such cases after analyzing the case.

Yasmin and Yaz contain drospirenone – a purported cure-all for everything from premenstrual syndrome to PMDD

The manufacturer of Yasmin and its competitor, Bayer, is facing lawsuits after the drug was found to cause serious side effects. Yasmin has been linked to a severe complication – blood clots. Symptoms include stroke and pulmonary embolism. Yaz has also been linked to high blood pressure. Women with gallbladder problems and liver tumors are advised to consult their doctors before taking either Yasmin or Yaz.

Although Yasmin and its generic equivalent, Yaz, have been found to cause serious side effects in some women. The FDA ordered Bayer to conduct a $20 million ad campaign to clarify the drug’s claims. Nonetheless, it’s difficult to imagine how women would use the pills without knowing the risks and possible side effects.

They contain estrogen and progestin to prevent pregnancy

A Bayer settlement paid out more than $2 billion to resolve the 2,000+ lawsuits filed against the drug maker over the birth control pills Yaz and Yasmin. The two birth control pills were linked to the development of life-threatening blood clots in women and potentially even caused some women to suffer fatalities. These settlements were made after the drug manufacturer analyzed each case to ensure it was not at fault.

Hundreds of women have filed legal claims against Bayer and Yasmin for causing their deep vein thrombosis and heart attacks. The two companies are facing multiple lawsuits that accuse them of hiding the risk factors and falsely advertising their products. The lawsuits allege that Bayer failed to warn consumers about the potential risk of deep vein thrombosis and the need to consult a doctor before taking birth control pills.

They cause sometimes-fatal clots

The new generation of birth control pills has been linked to a potentially deadly complication: blood clots. The risk of developing these clots is significantly higher than that of older birth control pills. About 10 percent of women on Yasmin or Yaz develop blood clots, while only seven percent of women who take older birth control pills develop clots. If not treated immediately, blood clots can cause heart attacks and strokes, and can block the lungs and blood vessels.

The new birth control pills, Yasmin and Yaz, contain drospirenone, a hormone linked to an increased risk of blood clots. Women taking these drugs are at a two to a threefold higher risk of venous thromboembolism. Researchers have also linked the use of Yaz to an increased risk of heart attack, stroke, and gallbladder disease.

They are sold by Bayer

Since launching in the marketplace, the fourth-generation birth control pills, Yasmin and Yazoo, have been the subject of intense litigation. Women who have taken the pills have claimed pulmonary embolism, deep vein thrombosis, gallbladder injury, strokes, and more. To date, Bayer has paid out more than $1.4 billion to settle these claims.

More than 9,000 lawsuits have been filed against Bayer for injuries caused by Yasmin and Yaz. The company has agreed to settle these claims, paying out nearly $142 million to Yaz and Yasmin victims. These settlements were reached after case-specific analysis. Fortunately for Yaz and Yasmin victims, Bayer has been forced to settle more claims to protect itself.

Two pension funds have filed a lawsuit against Bayer for alleged misrepresentation and concealment of risks. They allege that Bayer hid the health risks of these birth control pills and inflated their claims to increase profits. There are hundreds more lawsuits against Bayer, so you must contact a Bayer attorney if you have questions about your rights.

Leave a Reply

Your email address will not be published. Required fields are marked *